Impact of the COVID-19 Pandemic on Diagnostic Frequency of Febrile Seizures: An Electronic Health Record Database Observational Study.
COVID-19
febrile
pediatrics
seizures
Journal
The Neurohospitalist
ISSN: 1941-8744
Titre abrégé: Neurohospitalist
Pays: United States
ID NLM: 101558199
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
20
12
2022
Statut:
ppublish
Résumé
Febrile seizures are common in children and are associated with viral infection. Mitigation strategies implemented during the coronavirus disease 2019 (COVID-19) pandemic have slowed the spread of all viral illnesses potentially impacting febrile seizure frequency. The objective of this study is to assess the impact of COVID-19 mitigation strategies on the diagnostic frequency of febrile seizures. This was a retrospective observational cohort study utilizing TriNetX ® electronic health record (EHR) data. We included subjects aged 0 to 5 years of age reported to have a febrile seizure diagnosis. After the query, the study population was divided into 2 groups [pre-COVID-19 (April 1st, 2019 until March 31st, 2020) and COVID-19 (April 1st, 2020 until March 31st, 2021). We analyzed the following data: age, sex, race, diagnostic, medication, and procedural codes. During the pre-COVID time frame, emergency or inpatient encounters made up 688,704 subjects aged 0 to 5 years in the TriNetx database, while in the COVID-19 pandemic time frame, it made up of 368 627 subjects. Febrile seizure diagnosis frequency decreased by 36.1% [2696 during COVID-19 vs 7462 during the pre-COVID-19] and a higher proportion of status epilepticus was coded [72 (2.7%) vs 120 (1.6%)] ( Less children were diagnosed with febrile seizures during the COVID-19 pandemic, but a higher proportion were coded to have the complex subtype. The medical interventions required with the exception of antimicrobial use was similar. Further study is needed regarding mitigation strategies and its impact on pediatric diseases associated with viruses.
Sections du résumé
Background and Purpose
UNASSIGNED
Febrile seizures are common in children and are associated with viral infection. Mitigation strategies implemented during the coronavirus disease 2019 (COVID-19) pandemic have slowed the spread of all viral illnesses potentially impacting febrile seizure frequency. The objective of this study is to assess the impact of COVID-19 mitigation strategies on the diagnostic frequency of febrile seizures.
Methods
UNASSIGNED
This was a retrospective observational cohort study utilizing TriNetX ® electronic health record (EHR) data. We included subjects aged 0 to 5 years of age reported to have a febrile seizure diagnosis. After the query, the study population was divided into 2 groups [pre-COVID-19 (April 1st, 2019 until March 31st, 2020) and COVID-19 (April 1st, 2020 until March 31st, 2021). We analyzed the following data: age, sex, race, diagnostic, medication, and procedural codes.
Results
UNASSIGNED
During the pre-COVID time frame, emergency or inpatient encounters made up 688,704 subjects aged 0 to 5 years in the TriNetx database, while in the COVID-19 pandemic time frame, it made up of 368 627 subjects. Febrile seizure diagnosis frequency decreased by 36.1% [2696 during COVID-19 vs 7462 during the pre-COVID-19] and a higher proportion of status epilepticus was coded [72 (2.7%) vs 120 (1.6%)] (
Conclusions
UNASSIGNED
Less children were diagnosed with febrile seizures during the COVID-19 pandemic, but a higher proportion were coded to have the complex subtype. The medical interventions required with the exception of antimicrobial use was similar. Further study is needed regarding mitigation strategies and its impact on pediatric diseases associated with viruses.
Identifiants
pubmed: 36531856
doi: 10.1177/19418744221123208
pii: 10.1177_19418744221123208
pmc: PMC9557272
doi:
Types de publication
Journal Article
Langues
eng
Pagination
46-52Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Conrad Krawiec receives funding from the New England Journal of Medicine for educational materials and content.
Références
J Infect Dis. 2021 Nov 22;224(10):1751-1755
pubmed: 33830238
JAMA Neurol. 2021 May 1;78(5):588-595
pubmed: 33818596
Infect Dis Now. 2021 Aug;51(5):418-423
pubmed: 33991720
Nat Med. 2020 May;26(5):676-680
pubmed: 32371934
Am Fam Physician. 2019 Apr 1;99(7):445-450
pubmed: 30932454
Int J Environ Res Public Health. 2018 Oct 12;15(10):
pubmed: 30321985
Pediatr Pulmonol. 2021 Oct;56(10):3106-3109
pubmed: 34273135
J Infect Public Health. 2021 Sep;14(9):1186-1190
pubmed: 34399190
J Drug Target. 2020 Aug-Sep;28(7-8):742-754
pubmed: 32643436
Rev Clin Esp (Barc). 2021 Apr;221(4):247-248
pubmed: 33162562
Int J Environ Res Public Health. 2021 Sep 10;18(18):
pubmed: 34574472
Pediatrics. 2011 Feb;127(2):389-94
pubmed: 21285335
Lancet Child Adolesc Health. 2021 Dec;5(12):e44-e45
pubmed: 34695374
Crit Care Med. 2021 Dec 1;49(12):2033-2041
pubmed: 34259665
J Child Neurol. 2021 Aug;36(9):735-742
pubmed: 33754870
Pediatrics. 2021 Aug;148(2):
pubmed: 33986150
Acta Paediatr. 2021 Mar;110(3):939-940
pubmed: 33145819
Epilepsia. 2019 May;60(5):911-920
pubmed: 30980677
Pediatrics. 2021 Sep;148(3):
pubmed: 34215677
Children (Basel). 2020 Nov 17;7(11):
pubmed: 33212914
Drugs Context. 2018 Jul 16;7:212536
pubmed: 30038660
JAMA Netw Open. 2021 Jan 4;4(1):e2035281
pubmed: 33492377